WO2002000708A3 - Mutants of prostase - Google Patents

Mutants of prostase Download PDF

Info

Publication number
WO2002000708A3
WO2002000708A3 PCT/EP2001/007079 EP0107079W WO0200708A3 WO 2002000708 A3 WO2002000708 A3 WO 2002000708A3 EP 0107079 W EP0107079 W EP 0107079W WO 0200708 A3 WO0200708 A3 WO 0200708A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostase
protein
relates
mutants
homologues
Prior art date
Application number
PCT/EP2001/007079
Other languages
French (fr)
Other versions
WO2002000708A2 (en
Inventor
Silva Teresa Elisa Vir Cabezon
Martine Marchand
Y De Bassols Carlota Vinals
Original Assignee
Smithkline Beecham Biolog
Silva Teresa Elisa Vir Cabezon
Martine Marchand
Y De Bassols Carlota Vinals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog, Silva Teresa Elisa Vir Cabezon, Martine Marchand, Y De Bassols Carlota Vinals filed Critical Smithkline Beecham Biolog
Priority to AU2001285773A priority Critical patent/AU2001285773A1/en
Publication of WO2002000708A2 publication Critical patent/WO2002000708A2/en
Publication of WO2002000708A3 publication Critical patent/WO2002000708A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to novel proteins and to their production, from the prostase family. In particular, the invention relates to a genetically modified prostase wherein the protein is mutated in its active site. Such antigens may be formulated to provide vaccines for the treatment of prostate tumours. Methods for purifying prostase protein and homologues are also provided.
PCT/EP2001/007079 2000-06-27 2001-06-21 Mutants of prostase WO2002000708A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001285773A AU2001285773A1 (en) 2000-06-27 2001-06-21 Vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015736.2A GB0015736D0 (en) 2000-06-27 2000-06-27 Vaccine
GB0015736.2 2000-06-27

Publications (2)

Publication Number Publication Date
WO2002000708A2 WO2002000708A2 (en) 2002-01-03
WO2002000708A3 true WO2002000708A3 (en) 2002-05-16

Family

ID=9894505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007079 WO2002000708A2 (en) 2000-06-27 2001-06-21 Mutants of prostase

Country Status (4)

Country Link
AR (1) AR033378A1 (en)
AU (1) AU2001285773A1 (en)
GB (1) GB0015736D0 (en)
WO (1) WO2002000708A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786148A (en) * 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
EP0936270A2 (en) * 1998-02-12 1999-08-18 Basf Aktiengesellschaft Serin protease from prostate
US5955306A (en) * 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001004143A2 (en) * 1999-07-13 2001-01-18 Smithkline Beecham Biologicals S.A. Prostase vaccine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955306A (en) * 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
US5786148A (en) * 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
EP0936270A2 (en) * 1998-02-12 1999-08-18 Basf Aktiengesellschaft Serin protease from prostate
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001004143A2 (en) * 1999-07-13 2001-01-18 Smithkline Beecham Biologicals S.A. Prostase vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NELSON PETER S ET AL: "Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 6, 16 March 1999 (1999-03-16), March 16, 1999, pages 3114 - 3119, XP001038320, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2001285773A1 (en) 2002-01-08
WO2002000708A2 (en) 2002-01-03
GB0015736D0 (en) 2000-08-16
AR033378A1 (en) 2003-12-17

Similar Documents

Publication Publication Date Title
AU4981101A (en) Subtilisin variants
YU9403A (en) Anti-dual integrin antibodies, compositions, methods and uses
WO2001034801A3 (en) Recombinant gelatin in vaccines
WO2002031134A3 (en) Novel serine protease genes related to dppiv
WO2004016736A3 (en) Nucleic acids and corresponding proteins entitled 202p5a5 useful in treatment and detection of cancer
AU2002310321A1 (en) Compositions and methods for high-level, large-scale production of recombinant proteins
CA2341276A1 (en) Human anti-factor ix/ixa antibodies
WO2004098515A3 (en) Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
MY141459A (en) Recombinant anti-idiotypic antibodies
WO2001004143A3 (en) Prostase vaccine
WO2003022225A3 (en) Compositions comprising mixtures of therapeutic proteins and methods of producing the same
ATE512216T1 (en) NUCLEIC ACID AND THIS CORRESPONDING PROTEIN, CALLED 184P1E2, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER
WO2002000708A3 (en) Mutants of prostase
WO2002022848A3 (en) Compositions comprising mixtures of human cytokines and methods of producing the same
WO2002044366A3 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
ATE487735T1 (en) MAMMAL MILK GROWTH FACTOR
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
WO2002081514A3 (en) A novel f-box protein
WO2001029193A3 (en) Cell constructs that are suitable for immunotherapy, the production and the use thereof
WO2001075016A3 (en) A novel polypeptide, a human tyrosinase 16, and the polynucleotide encoding the polypeptide
ATE533507T1 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE DESIGNATION 238P1B2, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER
WO2001075029A3 (en) A novel polypeptide, nf-e2-associated human factor 11 and the polynucleotide encoding the polypeptide
WO2002000831A3 (en) A novel polypeptide, a bromine group domain 12 and the polynucleotide encoding the polypeptide
WO2001075011A3 (en) A novel polypeptide, cytochrome human constitution protein 10 and the polynucleotide encoding the polypeptide
WO2001075004A3 (en) A novel polypeptide, ubiquitine 9 conjugation enzyme and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP